Literature DB >> 3516217

alpha-Aminoboronic acid derivatives: effective inhibitors of aminopeptidases.

A B Shenvi.   

Abstract

alpha-Aminoboronic acids and their derivatives have been synthesized as stable white solids. These compounds are effective inhibitors of human enkephalin degrading aminopeptidase, microsomal leucine aminopeptidase (EC 3.4.11.2), and cytosolic leucine aminopeptidase (EC 3.4.11.1) at micro- to nanomolar concentrations. The inhibition of cytosolic leucine aminopeptidase has been studied in some detail. Kinetic data correspond to the mechanism for biphasic slow-binding inhibition: E + I in equilibrium E.I in equilibrium E.I*, in which a rapid initial binding is followed by a slow transformation to a stable enzyme inhibitor complex. The initial and final binding constants are dependent on the nature of the side chain at the alpha-carbon atom but are independent of the protecting group on the boronic acid moiety and follow the trend for the hydrolysis of the corresponding amino acid amides. The first-order rate constant for the transformation of E.I to E.I* is similar for all four compounds studied. These data suggest that the slow-binding step represents the formation of tetrahedral boronate species from trigonal boronic acid.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3516217     DOI: 10.1021/bi00354a014

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  8 in total

1.  Computer-aided design and activity prediction of leucine aminopeptidase inhibitors.

Authors:  J Grembecka; W A Sokalski; P Kafarski
Journal:  J Comput Aided Mol Des       Date:  2000-08       Impact factor: 3.686

Review 2.  Drug metabolism in the nasal mucosa.

Authors:  M A Sarkar
Journal:  Pharm Res       Date:  1992-01       Impact factor: 4.200

3.  The use of alpha-aminoboronic acid derivatives to stabilize peptide drugs during their intranasal absorption.

Authors:  M A Hussain; A B Shenvi; S M Rowe; E Shefter
Journal:  Pharm Res       Date:  1989-02       Impact factor: 4.200

4.  Cryptosporidium parvum metalloaminopeptidase inhibitors prevent in vitro excystation.

Authors:  P C Okhuysen; C L Chappell; C Kettner; C R Sterling
Journal:  Antimicrob Agents Chemother       Date:  1996-12       Impact factor: 5.191

Review 5.  Boron Chemicals in Drug Discovery and Development: Synthesis and Medicinal Perspective.

Authors:  Bhaskar C Das; Nitesh K Nandwana; Sasmita Das; Varsha Nandwana; Mohammed Adil Shareef; Yogarupa Das; Mariko Saito; Louis M Weiss; Frankis Almaguel; Narayan S Hosmane; Todd Evans
Journal:  Molecules       Date:  2022-04-19       Impact factor: 4.927

6.  Design of the first highly potent and selective aminopeptidase N (EC 3.4.11.2) inhibitor.

Authors:  H Chen; B P Roques; M C Fournié-Zaluski
Journal:  Bioorg Med Chem Lett       Date:  1999-06-07       Impact factor: 2.823

Review 7.  Metallo-aminopeptidase inhibitors.

Authors:  Artur Mucha; Marcin Drag; John P Dalton; Paweł Kafarski
Journal:  Biochimie       Date:  2010-05-10       Impact factor: 4.079

Review 8.  Aminopeptidase-N/CD13 (EC 3.4.11.2) inhibitors: chemistry, biological evaluations, and therapeutic prospects.

Authors:  Brigitte Bauvois; Daniel Dauzonne
Journal:  Med Res Rev       Date:  2006-01       Impact factor: 12.944

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.